Abstract
Mycosis fungoides is the most common form of cutaneous T-cell lymphomas. The related Sézary syndrome is a more aggressive form in which the skin is diffusely affected and the peripheral blood is involved. Although easily managed during its early phases, late-stage mycosis fungoides/Sézary syndrome is usually difficult to treat and becomes refractory to chemotherapy. Recently, promising case-based results have been obtained with alemtuzumab, a humanized immunoglobulin G1 monoclonal antibody that binds to CD52 cell surface antigens, in the treatment of advanced stage mycosis fungoides/Sézary syndrome. We report a case of Sézary syndrome treated successfully with alemtuzumab but who died of treatment-related infection.
MeSH terms
-
Alemtuzumab
-
Antibodies, Monoclonal / adverse effects*
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neoplasm / adverse effects*
-
Antibodies, Neoplasm / therapeutic use
-
Antigens, CD
-
Antigens, Neoplasm
-
Antineoplastic Agents / adverse effects*
-
Antineoplastic Agents / therapeutic use
-
CD52 Antigen
-
Cytomegalovirus / genetics
-
Cytomegalovirus / isolation & purification
-
Cytomegalovirus Infections / chemically induced*
-
DNA, Viral / analysis
-
Fatal Outcome
-
Glycoproteins / antagonists & inhibitors
-
Humans
-
Lymphopenia / chemically induced*
-
Male
-
Middle Aged
-
Opportunistic Infections / chemically induced*
-
Sezary Syndrome / drug therapy*
-
Sezary Syndrome / pathology
-
Skin / pathology
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neoplasm
-
Antigens, CD
-
Antigens, Neoplasm
-
Antineoplastic Agents
-
CD52 Antigen
-
CD52 protein, human
-
DNA, Viral
-
Glycoproteins
-
Alemtuzumab